公开(公告)号：WO2006079155A1

公开(公告)日：2006-08-03

申请号：PCT/AU2005/001757

申请日：2005-11-18

Applicant: APOLLO LIFE SCIENCES LIMITED ,  PRIEST, John D ,  WATTS, Alan D ,  WHITTAKER, Jason S ,  DOMAGALA, Teresa A ,  SIMPSON, Raina J ,  PILKINGTON, Glenn R ,  LIDDELL, Catherine A ,  BOEHM, Ingrid ,  LEE, Carol M Y

Inventor： PRIEST, John D ,  WATTS, Alan D ,  WHITTAKER, Jason S ,  DOMAGALA, Teresa A ,  SIMPSON, Raina J ,  PILKINGTON, Glenn R ,  LIDDELL, Catherine A ,  BOEHM, Ingrid ,  LEE, Carol M Y

IPC: C07K14/505 ,  A61P35/00 ,  C07H21/04

CPC classification number: C07K14/505 ,  C07K14/475 ,  C07K14/52 ,  C07K2319/00

Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule such as EPO, Flt3-Ligand, Flt3, PDGF-B or VEGF-165 or chimeric molecules thereof comprising at least a portion of the protein molecule, wherein the protein or chimeric molecule has a profile of measurable physiochemical parameters which is indicative of, associated with or forms the basis of, one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.

Abstract translation: 本发明一般涉及蛋白质，诊断学，治疗学和营养领域。 更具体地，本发明提供了分离的蛋白质分子，例如EPO，Flt3-配体，Flt3，PDGF-B或VEGF-165或其包含蛋白质分子的至少一部分的嵌合分子，其中所述蛋白质或嵌合分子具有 可测量的物理化学参数的概况，其指示与之相关联或形成一种或多种药理学性质的基础。 本发明进一步考虑了在诊断，预防，治疗，营养和/或研究应用范围内使用分离的蛋白质或其嵌合分子。

公开(公告)号：WO2006084337A1

公开(公告)日：2006-08-17

申请号：PCT/AU2006/000190

申请日：2006-02-14

Applicant: APOLLO LIFE SCIENCES LIMITED ,  PRIEST, John D ,  WATTS, Alan, D. ,  WHITTAKER, Jason, S. ,  DOMAGALA, Teresa A ,  LEE, Carol, M., Y. ,  SIMPSON, Raina, J. ,  BOEHM, Ingrid ,  JACKSON, Stuart ,  LIDDELL, Catherine A ,  PILKINGTON, Glenn, R. ,  CORBETT, Melissa

Inventor： PRIEST, John D ,  WATTS, Alan, D. ,  WHITTAKER, Jason, S. ,  DOMAGALA, Teresa A ,  LEE, Carol, M., Y. ,  SIMPSON, Raina, J. ,  BOEHM, Ingrid ,  JACKSON, Stuart ,  LIDDELL, Catherine A ,  PILKINGTON, Glenn, R. ,  CORBETT, Melissa

IPC: C07K14/715 ,  A61K38/17 ,  A61K38/20 ,  A61K38/21 ,  A61K39/395 ,  A61K45/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  C07H21/04 ,  C07K14/54 ,  C07K14/57 ,  C07K19/00 ,  G01N33/543

CPC classification number: G01N33/6869 ,  A61K38/00 ,  C07K14/5428 ,  C07K14/555 ,  G01N33/6866

Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule that comprises a dimeric 4-helix bundle, such as IFN-a2B, IFN-b1, IFN-g, IL-10 or its receptor, such as IFNAR2, IL-10Ra or chimeric molecules thereof comprising at least a portion of the protein molecule, such as IFN-a2B-Fc, IFN-bl -Fc, IFN-g-Fc, IFNAR2-Fc, IL-IO-Fc, IL-10Ra-Fc; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.

Abstract translation: 本发明一般涉及蛋白质，诊断学，治疗学和营养领域。 更具体地，本发明提供了包含二聚体4-螺旋束的分离的蛋白质分子，例如IFN-a2B，IFN-b1，IFN-g，IL-10或其受体，例如IFNAR2，IL-10Rα或嵌合体 包括蛋白质分子的至少一部分的分子，例如IFN-α2B-Fc，IFN-bl-Fc，IFN-g-Fc，IFNAR2-Fc，IL-10-Fc，IL-10Rα-Fc; 其中所述蛋白质或其嵌合分子具有可测量的生理化学参数的轮廓，其中所述轮廓指示，与一个或多个药理学性状的基础相关联或形成其基础。 本发明进一步考虑了在诊断，预防，治疗，营养和/或研究应用范围内使用分离的蛋白质或其嵌合分子。

公开(公告)号：WO2007142738A3

公开(公告)日：2008-03-20

申请号：PCT/US2007009114

申请日：2007-04-13

Applicant: ABBOTT CARDIOVASCULAR SYSTEMS ,  LUDWIG FLORIAN N ,  HOSSAINY SYED FAIYAZ AHMED ,  SRIDHARAN SRINIVASAN ,  LEE CAROL

Inventor： LUDWIG FLORIAN N ,  HOSSAINY SYED FAIYAZ AHMED ,  SRIDHARAN SRINIVASAN ,  LEE CAROL

IPC: A61L31/10 ,  A61L31/16

CPC classification number: A61L31/10 ,  A61L27/34 ,  A61L27/50 ,  A61L27/54 ,  A61L2300/406 ,  A61L2300/41 ,  A61L2300/416 ,  A61L2300/606 ,  A61M31/002

Abstract: Methods are disclosed for controlling the morphology and the release-rate of active agent from coating layers for medical devices comprising a polymer matrix and one or more active agents. The methods comprise fixing the morphology or phase distribution of the active agent prior to removing solvent from the coating composition. The coating layers can be used for controlled the delivery of an active agent or a combination of active agents.

Abstract translation: 公开了用于控制活性剂从包含聚合物基质和一种或多种活性剂的医疗装置的涂层的形态和释放速率的方法。 所述方法包括在从涂料组合物中除去溶剂之前固定活性剂的形态或相分布。 涂层可用于控制活性剂或活性剂的组合的递送。

公开(公告)号：WO2007142738A2

公开(公告)日：2007-12-13

申请号：PCT/US2007/009114

申请日：2007-04-13

Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC. ,  LUDWIG, Florian N. ,  HOSSAINY, Syed Faiyaz Ahmed ,  SRIDHARAN, Srinivasan ,  LEE, Carol

Inventor： LUDWIG, Florian N. ,  HOSSAINY, Syed Faiyaz Ahmed ,  SRIDHARAN, Srinivasan ,  LEE, Carol

IPC: A61L31/10 ,  A61L31/16

CPC classification number: A61L31/10 ,  A61L27/34 ,  A61L27/50 ,  A61L27/54 ,  A61L2300/406 ,  A61L2300/41 ,  A61L2300/416 ,  A61L2300/606 ,  A61M31/002

Abstract: Methods are disclosed for controlling the morphology and the release-rate of active agent from coating layers for medical devices comprising a polymer matrix and one or more active agents. The methods comprise fixing the morphology or phase distribution of the active agent prior to removing solvent from the coating composition. The coating layers can be used for controlled the delivery of an active agent or a combination of active agents.

Abstract translation: 公开了用于控制活性剂从包含聚合物基质和一种或多种活性剂的医疗装置的涂层的形态和释放速率的方法。 所述方法包括在从涂料组合物中除去溶剂之前固定活性剂的形态或相分布。 涂层可用于控制活性剂或活性剂组合的递送。

公开(公告)号：WO2006079176A1

公开(公告)日：2006-08-03

申请号：PCT/AU2006/000102

申请日：2006-01-27

Applicant: APOLLO LIFE SCIENCES LIMITED ,  PRIEST, John, D. ,  WATTS, Alan, D. ,  WHITTAKER, Jason, S. ,  DOMAGALA, Teresa, A. ,  PILKINGTON, Glenn, R. ,  BOEHM, Ingrid ,  LEE, Carol, M., Y. ,  LIM, Mei, Ann ,  THOMAS, Nikolien, S.

Inventor： PRIEST, John, D. ,  WATTS, Alan, D. ,  WHITTAKER, Jason, S. ,  DOMAGALA, Teresa, A. ,  PILKINGTON, Glenn, R. ,  BOEHM, Ingrid ,  LEE, Carol, M., Y. ,  LIM, Mei, Ann ,  THOMAS, Nikolien, S.

IPC: C07K14/525 ,  A61K38/17 ,  A61K38/19 ,  A61K39/395 ,  A61K45/00 ,  A61P17/00 ,  C07H21/04 ,  C07K14/715 ,  C07K19/00 ,  G01N33/543

CPC classification number: C07K14/70575 ,  A61K38/191 ,  C07K14/525 ,  C07K14/5255 ,  G01N33/6863

Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the tumour necrosis factor (TNF) superfamily such as TNF-a, Lymphotoxin-a (LT-a), TNFRI, TNFRII, OX40, BAFF, NGFR, Fas Ligand or chimeric molecules thereof comprising at least a portion of the protein molecule, such as TNF-a-Fc, LT-a-Fc, TNFRI-Fc, TNFRII-Fc, OX40-Fc, BAFF-Fc, NGFR-Fc, Fas Ligand-Fc; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.

Abstract translation: 本发明一般涉及蛋白质，诊断学，治疗学和营养领域。 更具体地，本发明提供了在肿瘤坏死因子（TNF）超家族中或与肿瘤坏死因子（TNF）a，Lymphotoxin-a（LT-a），TNFRI，TNFRII，OX40，BAFF，NGFR，Fas配体 或其嵌合分子，其包含蛋白质分子的至少一部分，例如TNF-α-Fc，LT-α-Fc，TNFRI-Fc，TNFRII-Fc，OX40-Fc，BAFF-Fc，NGFR-Fc，Fas配体 -fc; 其中所述蛋白质或其嵌合分子具有可测量的生理化学参数的轮廓，其中所述轮廓指示，与一个或多个药理学性状的基础相关联或形成其基础。 本发明进一步考虑了在诊断，预防，治疗，营养和/或研究应用范围内使用分离的蛋白质或其嵌合分子。

公开(公告)号：WO2006084327A1

公开(公告)日：2006-08-17

申请号：PCT/AU2006/000171

申请日：2006-02-09

Applicant: APOLLO LIFE SCIENCES LIMITED ,  PRIEST, John, D. ,  WATTS, Alan, D. ,  WHITTAKER, Jason, S. ,  DOMAGALA, Teresa, A. ,  LEE, Carol, M., Y. ,  THOMAS, Nikolien, S.

Inventor： PRIEST, John, D. ,  WATTS, Alan, D. ,  WHITTAKER, Jason, S. ,  DOMAGALA, Teresa, A. ,  LEE, Carol, M., Y. ,  THOMAS, Nikolien, S.

IPC: C07K19/00 ,  A61K38/17 ,  A61K45/00 ,  A61P31/12 ,  A61P31/18 ,  A61P35/04 ,  A61P37/02 ,  C07H21/04 ,  C07K14/47 ,  G01N33/543 ,  C07K14/705

CPC classification number: C07K14/70564 ,  A61K38/00 ,  C07K14/4726 ,  C07K14/485 ,  C07K14/7056 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/43 ,  G01N33/54306

Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule which comprises a C-type lectin or an EGF-like domain such as amphiregulin, CD209L, Langerin, L-selectin or chimeric molecules thereof comprising at least a portion of the protein molecule, such as amphiregulin-Fc, CD209L-Fc, Langerin S, Langerin L, Langerin L-FLAG, Langerin-Fc, L-selectin-Fc wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.

Abstract translation: 本发明一般涉及蛋白质，诊断学，治疗学和营养领域。 更具体地，本发明提供了分离的蛋白质分子，其包含C型凝集素或EGF样结构域，例如两性调节蛋白，CD209L，Langerin，L-选择素或其包含蛋白质分子的至少一部分的嵌合分子， 作为两性调节蛋白-Fc，CD209L-Fc，Langerin S，Langerin L，Langerin L-FLAG，Langerin-Fc，L-选择素-Fc，其中其蛋白质或嵌合分子具有可测量的生理化学参数的轮廓，其中该轮廓指示 ，与一种或多种药理学特征相关或形成基础。 本发明进一步考虑了在诊断，预防，治疗，营养和/或研究应用范围内使用分离的蛋白质或其嵌合分子。